Prucalopride Significantly Improves Bowel Function in Asia-Pacific Patients with Chronic Constipation
- Prucalopride 2 mg significantly increased spontaneous complete bowel movements (SCBMs) in Asia-Pacific patients with chronic constipation compared to placebo.
- 33.3% of prucalopride-treated patients experienced ≥3 SCBMs per week versus 10.3% on placebo over a 12-week period.
- Prucalopride demonstrated improvements in constipation-related symptoms and enhanced quality of life, with a rapid onset of action.
- The treatment was safe and well-tolerated, with no unexpected safety findings, supporting its use for chronic constipation in this population.